Immunome, Inc. · NASDAQ:IMNM
Immunome — Merger or Acquisition (July 2023)
27 slides from Immunome's merger presentation, July 2023
Slide 1: Morphimmune and Immunome Combined Corporate Presentation
Morphimmune and Immunome Combined Corporate Presentation July 2023
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Morphimmune, Inc. (“Morphimmune”) and Immunome, Inc. (“Immunome”) or a
Slide 3: Combining Morphimmune and Immunome as the First Step to Establishing a Preeminent Oncology Company
Combining Morphimmune and Morphimmune Immunome as the First Step to • Led by Dr. Clay Siegall, Seagen founder and long-time Chairman & CEO Establishing a Preeminent • Strong scientific basis from founder Dr. Philip Low, Oncology Company Professor at Purdue University and founder of Endocyte (acquire
Slide 4: Management Team with a Demonstrated Track Record of Success
Management Team with a Demonstrated Track Record of Success Clay Siegall, Ph.D. • Chief Executive Officer and Founder, Seagen (1998-2022) Searches for Chief President & Chief • Grew company to $2B+ revenue (2022) leading to pending $43B acquisition Medical Officer and Executive Officer Led developme
Slide 5: Combined Company Pipeline Overview
Combined Company Pipeline Overview Lead Development Anticipated Discovery IND-Enabling Optimization Candidate IND Filing Anti-IL-38 (IMM20320) Solid Tumors 1Q2024 FA-TLR7a (Mi-1001) Solid Tumors 4Q2024 177Lu-FAP (Morphimmune) Solid Tumors 1Q2025 Anti-EPN-1 (Immunome) Solid Tumors TBD Undisclosed Tar
Slide 6: Morphimmune and Immunome Merger Summary
Morphimmune and Immunome Merger Summary Overview Transaction Management & Programs • Morphimmune and Immunome • Expected ownership split is • Dr. Clay Siegall to serve as CEO of (NASD:IMNM) announced approximately 45% Morphimmune combined company with a highly planned merger in late June 2023 and 55
Slide 7: Combining Targeted Effector Technology with Antibody-Target Discovery Platform Brings Synergistic Value
Combining Targeted Effector Technology with Antibody-Target Discovery Platform Brings Synergistic Value Target Discovery Targeting Moieties Linkers Effectors • Screening strategy Small molecule ligands identifies antibodies to • No conjugation required known and unknown • Cleavable or non- • Ability
Slide 8: Programs: Anti-IL-38 (IMM20320)
Programs: Anti-IL-38 (IMM20320) MORPHIMMUNE + IMMUNOME 8
Slide 9: IL-38 Is an Immunosuppressive Cytokine with I/O Potential
IL-38 Is an Immunosuppressive Cytokine with I/O Potential IL-38 Function: Inhibits pro-inflammatory IL-36/IL-36R pathway1 I/O approach: Downregulation of IL-38 promotes innate immune activation • IL-38 knockout mice exhibit increased pro-inflammatory cytokine levels2 and delayed tumor growth3 Pathwa
Slide 10: Poor Survival for Cancer Patients with Tumors Expressing High IL-38
Poor Survival for Cancer Patients with Tumors Expressing High IL-38 Reduced Immune Cell Infiltration in IL-38 High Tumors Poor Overall Survival in IL-38 High Lung Cancer Key T Cells B Cells Kaplan-Meier curves according to IL-38 expression in HNSC HNSC HNSC patients with primary lung adenocarcinoma
Slide 11: IMM20320: Platform-Derived, Potential First-in-Class Anti-IL-38 mAb
IMM20320: Platform-Derived, Potential First-in-Class Anti-IL-38 mAb Inhibiting IL-38-mediated immunosuppression in cancer Human Protein Binding Array IL-38 Binding Inhibition Efficacy in B16.10 Melanoma 100 5000 1st dose IL-38 2000 SEM(mm3) (mm ) 3 Vehicle 80 4000 Anti-CTLA4 - 10 mg/ kg IL-38 ofIL-3
Slide 12: Programs: FA-TLR7a (Mi-1001)
Programs: FA-TLR7a (Mi-1001) MORPHIMMUNE + IMMUNOME 12
Slide 13: Developing a Successful TLR7a Requires a Differentiated Approach Targeting Immune Cells in the TME
We Believe Developing a Successful TLR7a Requires a Differentiated Approach That Directly Targets Immune Cells in Tumor Microenvironment • TLR7 is a pattern recognition receptor FRβ is expressed in the TME of Targeting FRβ restricts the scope of expressed in the endosome of many multiple solid cance
Slide 14: Mi-1001 is Novel Folate Receptor-Targeted TLR7a
Mi-1001 is Novel Folate Receptor-Targeted TLR7a Expected to Avoid Limitations of TLR7/8a Antibody Conjugates Shortcomings of Existing Approaches Morphimmune Approach • Systemic or intratumoral administration of non- Mi-1001 Structure Folate (Patent Pending) TLR7a-1A targeted TLR7/8a results in sever
Slide 15: Mi-1001 Shows in vivo Antitumor Activity Consistent with Active Immunotherapy Agent
Mi-1001 Shows in vivo Antitumor Activity Consistent with Active Immunotherapy Agent Human M2 Macrophage Assay Cytokine Levels in Healthy Mice Efficacy in 4T1 Breast Cancer Model 800 5000 1000 3 Control mm 600 4000 (pg/ mL) TLR7a 800 IL-6 (pg/ml) mIL-6(pg/mL) mm3 M i-1001 p<0.01 volume, M i-1001 ** 3
Slide 16: Programs: 177Lu-FAP
Programs: 177Lu-FAP MORPHIMMUNE + IMMUNOME 16
Slide 17: FAP Is a Promising RLT Target with Pan-Cancer Potential
FAP Is a Promising RLT Target FAP imaging shows high expression across with Pan-Cancer Potential 15 distinct tumor types • Fibroblast Activation Protein (FAP) is a cell surface protease with low expression in normal tissue • FAP is overexpressed on cancer associated fibroblasts (CAFs), the most comm
Slide 18: 177Lu-FAP Candidates are Rationally Designed Products Using Proprietary Targeted Effector Platform
177Lu-FAP Candidates Morphimmune’s Approach are Rationally Designed Products Using Proven structure used by Pluvicto and Lutathera to Proprietary Targeted Mi-3001 Structure: 12 linkers evaluated deliver Lu-177 isotope for impact on non-specific uptake Effector Platform FAP Ligand H O Linker HOOC Che
Slide 19: Developing 177Lu-FAP Candidates with Best-in-Class Potential
Developing 177Lu-FAP Candidates with Best-in-Class Potential In vivo data suggests albumin binder confers enhanced PK profile and biodistribution Total Absorbed Dose Rat IV PK 600 100000 Albumin Binding Albumin Binding Weak Weak 10000 500 Moderate concentration Moderate Plasmaconcentration 1000 Stro
Slide 20: Immunome Discovery Platform
Immunome Discovery Platform MORPHIMMUNE + IMMUNOME 20
Slide 21: Antibody Discovery Engine
Antibody Discovery Engine Drug Discovery Driven by Patient Immune Systems Patient responses unveil novel disease targets 01 02 03 04 Patient immune systems Memory B-cells are Antibodies are screened in Novel antibody-target recognize numerous isolated, expanded, and batches of up to 20,000 pairs are
Slide 22: Differentiated Approach Interrogates Memory B-Cells to Identify Validated and Novel Oncology Targets
Differentiated Approach Interrogates Memory B-Cells to Identify Both Validated and Novel Oncology Targets Identification of Well-Known Cancer Targets Validates Discovery Engine Target-specific Approach Literature Memory B-Cell Hybridoma Approach Increases Breadth of Screening Known Unknown 40000 300
Slide 23: High Throughput Platform Allows For Rapid Target Identification Across Multiple Cancer Types
High Throughput Platform Allows For Rapid Target Identification Across Multiple Cancer Types Diverse Cancer Catalog at Industrial Robust & Efficient Novel Target Landscape Scale Screening Discovery 70 Up to 14 140 20,000 Antibody-Target Pairs Cancers Libraries Antibodies Per Screen to Date 350+ ~250
Slide 24: Strategic Discovery Collaboration with AbbVie
Strategic Discovery Collaboration with AbbVie Key Financial Terms • AbbVie option to purchase worldwide rights for up to 10 novel target-antibody pairs arising from three specified tumor types • $30M upfront payment • Eligible for additional payments up to: ‒ $70M platform access payments (in additi
Slide 25: Near-Term Potential Inflection Points
Near-Term Potential Inflection Points 2023 2024 2025 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 IND Submission Anti-IL-38 PHASE 1 (IMM20320) IND Submission FA-TLR7a PHASE 1 (Mi-1001) Candidate Nomination IND Submission 177 Lu-FAP PHASE 1 Pipeline Expansion Organic pipeline expansion driven by Morphimmune and Imm
Slide 26: Prosecuting a Multi-Layered IP Strategy
Prosecuting a Multi-Layered IP Strategy COMPOSITION OF MATTER • Over 100 patents and patent applications across more than 20 families as of June 2023 • Covers Morphimmune’s targeting PLATFORM & DISCOVERY proprietary ligands and effectors, • Platform technologies and and lead conjugates for ligand- d
Slide 27: Building the Foundation for a Premier Targeted Oncology Company
Building the Foundation for a Premier Targeted Oncology Company • Experienced management team led by CEO Clay Siegall, Seagen co-founder and long-time chairman & CEO, with headquarters in Seattle • Immunome’s antibody expertise and target discovery platform complemented by Morphimmune’s Targeted Eff